Evidence analysisOctober 20, 2026Health & Science

Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 7, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Afqlir is an authorised biological medicine approved in the European Union on November 13, 2024, for the treatment of several serious eye conditions, including wet age-related macular degeneration (AMD), macular oedema related to retinal vein occlusion and diabetes, and myopic choroidal neovascularisation. It is a biosimilar to the previously authorised medicine Eylea, both containing the active substance aflibercept. Aflibercept works by inhibiting vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF), proteins that drive abnormal blood vessel growth and leakage in affected eyes.

Laboratory and clinical studies demonstrate that Afqlir has a highly similar structure, purity, and biological activity to Eylea. In a clinical study involving 485 patients with wet AMD, Afqlir was shown to be as effective as Eylea, with both groups experiencing similar improvements in vision measured by letter recognition on a standard eye test after eight weeks of treatment. The safety profile observed for Afqlir is comparable to that of the reference medicine, with common side effects including conjunctival haemorrhage, retinal haemorrhage, reduced vision, and eye pain.

What the source claims

  • Afqlir is a biosimilar to the established anti-VEGF medicine Eylea, meaning it matches the reference product in quality and clinical effect.
  • The medicine is given by intravitreal injection and dosing frequency depends on the specific eye condition and patient response.
  • Aflibercept blocks VEGF-A and PlGF, proteins involved in pathological blood vessel growth and leakage, thus controlling swelling and preserving vision.
  • The European Medicines Agency (EMA) assessed evidence demonstrating equivalence in safety and efficacy between Afqlir and Eylea, meeting EU standards for biosimilars.
  • Common side effects occur at frequencies comparable to the reference medicine, while serious injection-related adverse events are rare but significant, including risks such as blindness and endophthalmitis.
  • Pharmaceutical companies marketing Afqlir are required to provide educational materials to patients and healthcare professionals to support safe administration and early recognition of side effects.

What may be missing from the usual framing

The European public assessment report mainly focuses on regulatory approval standards for biosimilars, which allow reliance on prior clinical data of the reference product to reduce the need for extensive new clinical trials. This regulatory approach means some uncertainties remain about long-term outcomes or effects in populations not extensively covered in initial studies.

Information on comparative cost-effectiveness, patient access, and real-world use data for Afqlir beyond the initial wet AMD study is limited in the public EPA report. There is also minimal discussion on the transparency of manufacturer relationships, pricing pressures, or prescribing incentives, which may influence uptake of biosimilars in healthcare systems.

The report highlights common and serious side effects but does not elaborate extensively on management protocols for rare adverse events or outcomes in off-label contexts.

Competing evidence or uncertainty

At present, the primary comparative clinical evidence is a single key study in patients with wet AMD, showing equivalence to the reference medicine. However, clinical outcomes in other indications authorised for Afqlir such as diabetic macular oedema or myopic choroidal neovascularisation rely largely on extrapolation from Eylea data, permitted under biosimilar regulatory pathways but representing a limitation in direct evidence.

Post-marketing surveillance and ongoing pharmacovigilance are essential to monitor for rare or delayed adverse events and to validate real-world efficacy. The balance of benefits versus risks may vary in broader patient populations or with longer follow-up, but currently available evidence is considered sufficient by EMA regulators for authorisation.

Why it matters

The approval of Afqlir as a biosimilar to Eylea offers the potential for increased treatment options and competition in the market for serious ocular diseases that can lead to vision loss. Biosimilars can reduce treatment costs and improve patient access to life-preserving medications.

Given the severity of the treated conditions and the invasiveness of intravitreal injections, ensuring similarity in safety and effectiveness to an established product is crucial. Availability of multiple biosimilar options may also pressure healthcare systems and manufacturers to optimize pricing and delivery protocols.

Nonetheless, the reliance on biosimilar pathways highlights the need for careful real-world monitoring and transparent reporting on patient outcomes and adverse effects to maintain confidence among physicians and patients.

What to verify next

  • Ongoing real-world data collection regarding the safety and effectiveness of Afqlir in all authorised indications beyond wet AMD.
  • Comparative cost and reimbursement policies between Afqlir, Eylea, and other competitors in the European and wider markets.
  • Details on pharmacovigilance plans, including responsiveness to reported side effects and implementation of risk minimization measures.
  • Patient and healthcare professional education efforts and their impact on treatment adherence and early identification of adverse events.
  • Additional peer-reviewed studies or registry data that may clarify the long-term outcomes, including in less common treated conditions.

Readers interested in further detail should consult the original European Medicines Agency sources for Afqlir to review comprehensive regulatory assessments and product information.

Source & verification

Primary source: What's new · October 20, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

Burkina Faso Targets Critics in Exile

Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…